The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable

Detalles Bibliográficos
Autor principal: Jensen, Chelsee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Perspectives on Value
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391150/
https://www.ncbi.nlm.nih.gov/pubmed/34464211
http://dx.doi.org/10.18553/jmcp.2021.27.9.1321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391150/
https://www.ncbi.nlm.nih.gov/pubmed/34464211
http://dx.doi.org/10.18553/jmcp.2021.27.9.1321

Ejemplares similares